The new phenol-imidazole pro-ligands (R)LH react with Co(BF(4))(2).6H(2)O in the presence of Et(3)N to form the corresponding [Co(II)((R)L)(2)] compound (R = Ph (1), PhOMe (2), or Bz (3)). Also, (Bz)LH, reacts with Co(ii) in the presence of Et(3)N and H(2)O(2) to form [Co(III)((Bz)L)(3)](4). The structures of 1.2.5MeCN, 2.2DMF, 3.4MeOH, and 4.4DMF have been determined by X-ray crystallography. 1, 2, and 3 each involve Co(II) bound to two N,O-bidentate ligands with a distorted tetrahedral coordination sphere; 4 involves Co(III) bound to three N,O-bidentate ligands in a mer-N(3)O(3) distorted octahedral geometry. [Co(II)((R)L)(2)](R = Ph or PhOMe) undergo two, one-electron, oxidations. The products of the first oxidation, [1](+) and [2](+), have been synthesised by the chemical oxidation of 1 and 2, respectively; these cations, formulated as [Co(II)((R)L*)((R)L)(2)](+), comprise one phenoxyl radical and one phenolate ligand bound to Co(II) and are the first phenoxyl radical ligand complexes of tetra-coordinated Co(II). 4 undergoes two, one-electron, ligand-based oxidations, the first of which produces [4](+), [Co(III)((Bz)L*)((Bz)L)(2)](+). Unlike [1](+) and [2](+), product of the one-electron oxidation of [Co(II)((Bz)L)(2)], [3](+), is unstable and decomposes to produce [4](+). These studies have demonstrated that the chemical properties of [M(II)((R)L*)((R)L)(2)](+)(M = Co, Cu, Zn) are highly dependent on the nature of both the ligand and the metal centre.
No takes yet. Share an insight, caveat, or question.
Benisvy et al. (2004) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: